Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 11/20 | 1.00 |
| ▸ | LMNA | P02545 | 6/20 | 1.00 |
| ▸ | TSHR | P16473 | 5/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 3/20 | 1.00 |
| ▸ | HPGD | P15428 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.82 |
| ▸ | MEN1 | O00255 | 8/20 | 0.82 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.82 |
| ▸ | GAA | P10253 | 2/20 | 0.82 |
| ▸ | HTT | P42858 | 1/20 | 0.82 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.82 |
| ▸ | TP53 | P04637 | 2/20 | 0.82 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.82 |
| ▸ | RAB9A | P51151 | 3/20 | 0.62 |
| ▸ | NPC1 | O15118 | 2/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2534117 | 0.90 | KMT2A (1.00) | MAPTLMNATSHRSMN1; SMN2MAPK1 | |
| SCHEMBL2533817 | 0.90 | MAPT (1.00) | MAPTLMNATSHRSMN1; SMN2MAPK1 | |
| SCHEMBL2535208 | 0.86 | MAPT (1.00) | MAPTLMNATSHRSMN1; SMN2MAPK1 | |
| SCHEMBL24711194 | 0.82 | KMT2A (0.71) | MAPTLMNATSHRSMN1; SMN2MAPK1 | |
| SCHEMBL2534437 | 0.80 | LMNA (1.00) | MAPTLMNATSHRSMN1; SMN2MAPK1 | |
| SCHEMBL11130131 | 0.78 | MAPT (0.64) | MAPTLMNATSHRSMN1; SMN2MAPK1 | |
| SCHEMBL6632076 | 0.77 | NPC1 (1.00) | MAPTLMNATSHRSMN1; SMN2MAPK1 | |
| SCHEMBL259427 | 0.76 | KCNK3 (0.82) | MAPTLMNASMN1; SMN2MAPK1HPGD | |
| SCHEMBL19419914 | 0.75 | NPC1 (0.78) | MAPTLMNATSHRSMN1; SMN2MAPK1 | |
| SCHEMBL1846669 | 0.74 | RAB9A (0.83) | MAPTLMNATSHRSMN1; SMN2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110257182-A1 | Novel amido derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors | BOLEA CHRISTELLE | 2011-10-20 | — | — | US | claimed |
| US-20100137336-A1 | NOVEL AMIDO DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMA SA (CH) | 2010-06-03 | — | — | US | claimed |
| EP-2181091-A2 | AMIDO DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | Addex Pharmaceuticals SA (CH) | 2010-05-05 | — | — | EP | claimed |
| WO-2009010454-A2 | AMIDO DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMA S.A. (CH) | 2009-01-22 | — | — | WO | claimed |
| US-8524726-B2 | Amido derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors | ADDEX PHARMA S.A. (CH) | 2013-09-03 | — | — | US | disclosed |
| US-20130137704-A1 | NOVEL AMIDO DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | Addex Pharma, SA (CH) | 2013-05-30 | — | — | US | disclosed |
| US-20130131092-A1 | NOVEL AMIDO DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | Addex Pharma, SA (CH) | 2013-05-23 | — | — | US | disclosed |
| US-20110257182-A1 | Novel amido derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors | BOLEA CHRISTELLE | 2011-10-20 | — | — | US | disclosed |
| US-20100137336-A1 | NOVEL AMIDO DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMA SA (CH) | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130137704-A1 | NOVEL AMIDO DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | GRM4, GRM1, GRM3 | MAPT 1940/4885LMNA 4614/4885TSHR 390/4885 |
| US-20100137336-A1 | NOVEL AMIDO DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | GRM4, GRM1, GRM3 | MAPT 1940/4885LMNA 4614/4885TSHR 390/4885 |
| US-20110257182-A1 | Novel amido derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors | GRM4, GRM1, GRM3 | MAPT 1940/4885LMNA 4614/4885TSHR 390/4885 |
| US-20130131092-A1 | NOVEL AMIDO DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | GRM4, GRM1, GRM3 | MAPT 1940/4885LMNA 4614/4885TSHR 390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.